CYTK Cytokinetics, Incorporated

50.78USD-1.32%Mkt Cap: 7.07B USDP/E: —

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the Unit…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap7.07B USD
Enterprise Value7.47B USD
Revenue (TTM)113.29M USD
Gross Profit-327.99M USD
Net Income (TTM)-784.96M USD
Revenue/Share0.88 USD
Last Price50.78 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees673
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.09
PEG—
EV/EBITDA-10.75
EV/Revenue65.90
P/S62.44
P/B-22.01
EPS (TTM)-6.02 USD
EPS (Forward)-4.23 USD
52W Range
50.321% of range88.31
52W High88.31 USD
52W Low50.32 USD
Profitability
Gross Margin-372.55%
Oper. Margin-625.15%
EBITDA Margin0.00%
Profit Margin-891.60%
ROE119.00%
ROA-55.10%
ROIC—
ROCE-50.10%
Growth
Revenue Growth2356.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-510.01M USD
CapEx (TTM)24.81M USD
FCF Margin-356.01%
FCF Yield-5.70%
Net Debt296.84M USD
Net Debt/EBITDA-0.43
Net Debt/FCF—
Balance Sheet
Debt/Equity-1.95
Current Ratio3.36
Quick Ratio3.29
Book Value/Sh-2.31 USD
Cash/Share8.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateJun 25, 2013
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)109.42 USD
Upside (mean)+115.5%
Target Range78.00 USD – 146.00 USD
78.00+115.5% to mean146.00
# Analysts19
Ownership
Shares Out.139.30M
Float138.78M
Insiders0.58%
Institutions127.40%
Short Interest
Short Ratio10.0d
Short % Float19.65%
Short % Out.12.88%
Shares Short17.93M
Short (prev mo.)19.33M
Technical
SMA 5062.79 (-19.1%)
SMA 20069.59 (-27.0%)
Beta0.47
S&P 52W Chg12.00%
Avg Vol (30d)1.89M
Avg Vol (10d)2.67M
Technical Indicators
RSI (14)29.6
MACD-3.2667
MACD Signal-2.7534
MACD Hist.-0.5133
BB Upper66.42 USD
BB Middle57.38 USD
BB Lower48.33 USD
BB Width31.52%
ATR (14)2.618 USD
Vol Ratio (20d)0.69x

About Cytokinetics (NASDAQ: CYTK)

›

Cytokinetics (NASDAQ: CYTK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 673 employees.

The shares were at 50.78 USD on 20 November 2026, down 15.6% over 52 weeks. Its 52-week range is 50.32 USD to 88.31 USD, and it trades at the bottom of that range.

Its market capitalisation is 7.07B USD.

Cytokinetics reports return on equity of 119.0%.

Its debt exceeds its cash by 296.84M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 19 analysts cover the stock, with an average rating of Buy; their mean price target of 109.42 USD is 115.5% above the current price. The next earnings report is expected on 24 February 2027.